BioSpace News Archive

Oshi Health announced strategic investments by the American College of Gastroenterology and the American Gastroenterological Association GI Opportunity Fund.

Curebase, a company committed to democratizing access to clinical studies and a leader in decentralized clinical trial execution, is now offering Omnisite™, a flexible site model that leverages a number of the company’s existing capabilities to reach patients where they are at home and in real-world medical settings.

Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company’s first-in-class telomerase inhibitor, in patients with acute myeloid leukemia (AM)L, or higher risk myelodysplastic syndromes (MDS), who are relapsed/refractory/intolerant to hypomethylating agents (HMAs).

Cardio Diagnostics Holdings, Inc, a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the publication of groundbreaking research in the journal Genes.

Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.

Adaptive Phage Therapeutics announced that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.

Aytu BioPharma, Inc. announced the closing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of 1,743,695 shares of its common stock.

Class I major histocompatibility complex proteins play an essential role in the immune system of all jawed vertebrates.

Oculis Holding AG announced that the underwriters of its previously announced public offering of ordinary shares, which closed on June 5, 2023, have partially exercised their option to purchase an additional 154,234 ordinary shares at a public offering price per share of $11.50, resulting in additional gross proceeds to Oculis of approximately $1.8 million.

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that in accordance with Nasdaq rules regarding employment inducement awards, the Company has granted an equity compensation award to a new employee.